Company* |
Funding |
Amount |
Type | Details (Date) |
Aureus Pharma* |
European Union |
ND |
European Eureka project related to hepatotoxicity, as well |
The firms, along with Sanofi-Aventis and Budapest University, will build a knowledge base (Hungary) as accompanying predictive tools (5/16) |
Aradigm |
Defence R&D Canada |
$0.663 |
Funding support |
The extending funding will support a preclinical study of inhaled liposomal ciprofloxacin for post- exposure prophylaxis against inhalational anthrax (4/26) |
Arbor Vita Corp.* |
National Cancer Institute |
$0.6 |
Phase I SBIR grant |
Arbor Vita and the nonprofit organization will use funds to develop a lateral flow test to detect precancerous cervical lesions using E6, a protein marker (6/28) |
Arteriocyte |
State of Ohio |
$0.6 |
Grant |
The grant, part of an $8M award to Cleveland's Center for Stem Cell and Regenerative Medicine, will be used in development of Arteriocyte's stem cell technology (5/19) |
Athersys Inc.* |
State of Ohio |
$3.5 |
Third Frontier Program funding |
Athersys is getting $3.5M of a total of $8M awarded to the Center for Stem Cell and Regenerative Medicine, which was founded by Athersys and includes a number of institutions in Ohio (5/15) |
Avecia Biotechnology |
National Institute of Allergy and Infectious Diseases |
$3.9 |
Grant |
Funding will support Avecia's development of a version of Thraxine, a recombinant protective antigen-based anthrax vaccine, with increased stability (6/12) |
AvidBiotics |
National Institutes of Health |
ND |
Phase I SBIR grant |
The grant will support work on development of a class of agents against plague (5/8) |
BioNanomatrix |
National Cancer Institute |
ND |
SBIR grant |
Funds will support development of the company's technology for cancer detection devices and methodologies (5/17) |
Cangene Corp. |
Department of Health and Human Services |
$362 |
Project BioShield contract |
The five-year contract covers development and supply of 200,000 doses of botulinum toxin immune globulin; the contract requires Cangene get FDA approval of the product (5/31) |
CellCentric |
UK Department of Trade and Industry |
£1.15 ($2.1) |
Technology Program award |
CellCentric and three research institutions are getting a total of £2.3M for a program in epigenetics; partners are the Gurdon Institute, the Babraham Institute and the University of Nottingham (5/4) |
CombiMatrix |
U.S. Army Research Office |
$1.9 |
Contract |
The new funding will support development of a device for detecting a variety of microorganisms within one hour (4/24) |
CombiMatrix |
The National Academies |
ND |
Keck Futures Initiative grant |
CombiMatrix and Texas A&M University will use the funds on a method to increase the speed of hybridization in DNA microarray applications (4/11) |
CombinatoRx |
The Economic Development Board of Singapore |
ND |
Research Incentive Scheme for Companies grant |
CombinatoRx's Singapore subsidiary will use the funds to support research and development in the area of infectious diseases (4/21) |
Cyntellect |
National Science Foundation |
$0.5 |
Phase IIB SBIR grant |
Funding will support development of Cyntellect's laser-based LEAP system for enhancing RNA interference applications (6/27) |
CytImmune |
National Cancer Institute |
$0.5 |
Phase I SBIR grant |
Funds will support development of the pegylated colloidal gold tumor-targeting nanotechnology product CTY-21001 (3/30) |
Epeius |
Lazarex Cancer Foundation |
$0.4 |
Grant |
Funds will support ongoing gene therapy trials of Rexin-G for treating advanced pancreatic cancer (6/19) |
GammaCan |
Israel-U.S. Binational Industrial Research and Development Foundation |
$1 |
Grant |
Funding will support development of VitiGam, an IgG-based immunotherapy product for treating patients with Stage III and IV melanoma (6/21) |
GenVec Inc. |
Naval Medical Research Center |
$0.5 |
Contract award |
Funding will support work on GenVec's adenovector-based malaria vaccines; it is the third year of funding for the program (4/27) |
Human |
Department of Health and Human Services |
$165 |
Project BioShield contract |
Following the first phase of the contract, HHS exercised its option to purchase 20,000 courses of ABthrax, a product for preventing and treating anthrax infection (6/20) |
Lexicon |
U.S. Army Medical Research & Materiel Command |
$2 |
Grant |
The one-year initial term of the grant calls for Lexicon to identify targets for development of drugs to treat or prevent spinal muscular atrophy (5/11) |
MedImmune |
U.S. Department of Health and Human Services |
$170 |
Contract award |
Five-year award will fund work on cell- ased seasonal and pandemic vaccines that use live, attenuated, needle-free influenza vaccine technology (5/4) |
Micronics Inc.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
Funds will support work with the Fred Hutchinson Cancer Research Center to develop a point-of-care diagnostic system for early detection of colon cancer (4/11) |
Neurodem |
The Michael J. Fox Foundation for Parkinson's Research |
$0.49 |
Grant |
Funds will support development of a transdermal patch for continuous delivery of levodopa (5/12) |
Oragenics Inc. |
National Science Foundation |
ND |
Phase I SBIR grant |
Research will focus on production of analogues from the class of antibiotics called lantibiotics (5/2) |
Panacea |
National Heart, Lung and Blood Institute |
$0.88 |
Phase II SBIR grant |
Funding will be used to complete preclinical studies of PAN-811, a neuroprotective agent being developed to treat ischemic stroke (6/21) |
Peregrine |
U.S. Department of Defense |
$0.46 |
Grant |
Collaborators at the University of Texas Southwestern Medical Center will use the funds to study Peregrine's anti-phospholipid agent bavituximab (Tarvacin) for imaging and treating recurrent breast cancer (4/25) |
Pharmos |
Israeli Ministry of Industry and Trade |
$1.3 |
Grant |
Up to $1.3M in funding will be provided to support candidates from Pharmos' CB2- selective platform of synthetic cannabinoids (4/10) |
Prothera |
National Institutes of Health |
$1.8 |
Phase II SBIR grant |
Funding will support studies of of therapeutic proteins designed to restore the proper balance of inter-alpha inhibitor proteins for treating sepsis (6/27) |
Prothera |
National Institute of Allergy and Infectious Diseases |
$1 |
Phase I STTR grant |
Funding will support development of inter- alpha inhibitor proteins as a therapeutic for exposure to the anthrax bacterium (6/27) |
Reaction |
National Cancer Institute |
$0.94 |
SBIR grant |
RBC will use the funding to migrate the current well-plate radioisotope methods onto its DiscoveryDot nanoliter screening platform (6/20) |
Sirtris |
The ALS Association |
ND |
Research grant |
Funds will support research on a compound that activates sirtuins for the treatment of amyotrophic lateral sclerosis (4/21) |
Solazyme Inc.* |
Not disclosed |
ND |
Phase I STTR grant |
Funds will be used to pursue genetic engineering of Dunaliella, a green eukaryotic microalgae; Solazyme will work with Brooklyn College in the project (6/21) |
Starpharma |
National Institute of Allergy and Infectious Diseases |
ND |
Funding support |
The NIAID will fund a clinical trial to test VivaGel in the prevention of genital herpes; funding is in addition to $20.3M being provided to test the microbicide for the prevention of HIV (4/19) |
Theratechnologies |
National Institute on Aging |
$2.6 |
Grant |
Funds will support a clinical trial of the company's TH9507 on cognitive function in healthy and mildly impaired older adults (3/28) |
| Notes: | ||||
| * Indicates a privately held company. | ||||
| Currency conversions reflect values at the time of a deal's announcement. | ||||
| SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
| Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
| AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.